Seres (MCRB) EVP reports RSU settlement and small tax-cover sale
Rhea-AI Filing Summary
Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (Ticker: MCRB), reported vesting and settlement of restricted stock units and a small sale of common stock in August 2025. On 08/15/2025 two tranches of restricted stock units were reported (133 and 97 RSUs) that represent contingent rights to receive shares; the filings show post-transaction beneficial ownership figures of 5,177 and 5,274 shares respectively. On 08/18/2025 the reporting person sold 59 shares at $16.65, executed under a Rule 10b5-1 instruction adopted March 5, 2023, described as intended solely to cover taxes relating to RSU vesting. The Form 4 is signed by an attorney-in-fact on 08/19/2025.
Positive
- RSU vesting disclosed, showing alignment of executive compensation with equity ownership
- Sale executed under a Rule 10b5-1 plan, indicating pre-planned, non-discretionary disposition to cover taxes
Negative
- Small reduction in direct holdings after the tax-cover sale (59 shares sold)
Insights
TL;DR: Small RSU settlements and a tax-cover sale under a 10b5-1 plan; not materially dilutive.
The reported activity shows executive compensation vesting (two RSU tranches) and a modest sale of 59 shares at $16.65 to cover tax obligations under a pre-existing Rule 10b5-1 plan. The transactions are routine for equity-based compensation and do not indicate a change in company guidance, financing or control. The net change in beneficial ownership is modest relative to the share counts reported, suggesting limited market impact.
TL;DR: Proper disclosure of RSU vesting and planned sale demonstrates compliance with Section 16 reporting.
The Form 4 documents that the sales were effected pursuant to a 10b5-1 instruction and explains vesting schedules for the RSUs. The filing includes required detail on amounts acquired and disposed and is executed by an attorney-in-fact, which is common for insider reports. No indications of atypical governance or undisclosed compensation changes are present in the document.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 59 | $16.65 | $982.35 |
| Exercise | Restricted Stock Units | 133 | $0.00 | -- |
| Exercise | Restricted Stock Units | 97 | $0.00 | -- |
| Exercise | Common Stock | 133 | $0.00 | -- |
| Exercise | Common Stock | 97 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
